Transplantation pancréatique : indications, résultats et perspectives

EMC - Endocrinologie Pub Date : 2004-01-01 DOI:10.1016/j.emcend.2003.10.002

B Barrou (Professeur des Universités, Praticien hospitalier) , M.-O Bitker (Professeur des Universités, praticien hospitalier) , A Grimaldi (Professeur des Universités, praticien hospitalier) , P Debré (Professeur des Universités, praticien hospitalier) , F Richard (Professeur des Universités, praticien hospitalier)

{"title":"Transplantation pancréatique : indications, résultats et perspectives","authors":"B Barrou (Professeur des Universités, Praticien hospitalier) , M.-O Bitker (Professeur des Universités, praticien hospitalier) , A Grimaldi (Professeur des Universités, praticien hospitalier) , P Debré (Professeur des Universités, praticien hospitalier) , F Richard (Professeur des Universités, praticien hospitalier)","doi":"10.1016/j.emcend.2003.10.002","DOIUrl":null,"url":null,"abstract":"<div><p>Pancreas transplantation is now a well established treatment for type I diabetes. More than 17 000 cases have been reported to the International Pancreas Transplant Registry. One year graft survival is around 80%. The majority of the cases are combined kidney and pancreas transplants harvested from the same donor in type I diabetics with an advanced nephropathy. However, the recent progresses in the field of immunosuppression have improved the results of isolated pancreas transplants or pancreas after kidney transplants. These 2 categories are not very frequent in Europe but could be more frequently offered in light of these results. Major breakthrough have also been done in the field of islets transplantation. A multicenter trial is currently in progress to assess whether the excellent results reported by a Canadian group are reproducible or not. If yes, this technique could have a place of choice for pancreatic endocrine function replacement.</p></div>","PeriodicalId":100422,"journal":{"name":"EMC - Endocrinologie","volume":"1 1","pages":"Pages 43-53"},"PeriodicalIF":0.0000,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.emcend.2003.10.002","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMC - Endocrinologie","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1762565303000042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Pancreas transplantation is now a well established treatment for type I diabetes. More than 17 000 cases have been reported to the International Pancreas Transplant Registry. One year graft survival is around 80%. The majority of the cases are combined kidney and pancreas transplants harvested from the same donor in type I diabetics with an advanced nephropathy. However, the recent progresses in the field of immunosuppression have improved the results of isolated pancreas transplants or pancreas after kidney transplants. These 2 categories are not very frequent in Europe but could be more frequently offered in light of these results. Major breakthrough have also been done in the field of islets transplantation. A multicenter trial is currently in progress to assess whether the excellent results reported by a Canadian group are reproducible or not. If yes, this technique could have a place of choice for pancreatic endocrine function replacement.

查看原文本刊更多论文

胰腺移植:适应症、移植结果及前景

胰腺移植现在是治疗I型糖尿病的一种行之有效的方法。国际胰腺移植登记处报告了超过17000例病例。一年的移植存活率约为80%。大多数病例是来自同一供体的1型糖尿病晚期肾病患者的肾脏和胰腺联合移植。然而，近年来免疫抑制领域的进展改善了孤立胰腺移植或肾移植后胰腺的结果。这两个类别在欧洲不是很常见，但根据这些结果，可以更频繁地提供。在胰岛移植领域也取得了重大突破。目前正在进行一项多中心试验，以评估加拿大小组报告的优异结果是否可重复。如果是，这项技术可能是胰腺内分泌功能替代的一个选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EMC - Endocrinologie

自引率

0.00%

发文量